|
|
|
|
|
|
|
|
abstract
Expert Opinion on Pharmacotherapy - Drug Evaluation: Olaparib for the Treatment of Epithelial Ovarian Cancer
Introduction: Despite recent advances in the management of epithelial ovarian cancer, overall survival rates remain poor, and there is a pressing need to develop novel therapeutic agents and maintenance strategies to improve outcomes for women with this disease. Olaparib, a potent oral poly(ADP-ribose) polymerase (PARP) inhibitor, has demonstrated antitumor activity in women with ovarian cancer, associated with homologous recombination deficiency.
Areas
covered: This review outlines the rationale for PARP inhibitor therapy
in ovarian cancer and summarizes the efficacy and tolerability data for
olaparib to date. Ongoing phase III clinical trials of olaparib in
ovarian cancer will be discussed.
Expert
opinion: There are a number of issues regarding the optimal use of
olaparib in ovarian cancer, including the identification of a homologous
recombination deficiency signature to predict treatment response,
establishment of the optimal treatment setting (maintenance or relapsed
disease), and evaluation of cost-effectiveness. Finally, the long term
consequences of PARP inhibitors, including the risk of myelodysplasia
and acute myeloid leukemia need to be quantified in ongoing large phase
III clinical trials.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.